<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="828">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00192621</nctid>
  <trial_identification>
    <studytitle>Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects</studytitle>
    <scientifictitle>A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ACTR012605000661673</secondaryid>
    <secondaryid>SAMA 002 Version 5</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <healthcondition>Dyslipidemias</healthcondition>
    <healthcondition>Glucose Metabolism Disorders</healthcondition>
    <healthcondition>Metabolic Diseases</healthcondition>
    <healthcondition>Lipodystrophy</healthcondition>
    <healthcondition>Cardiovascular Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Combivir (zidovudine [AZT] / lamivudine [3TC])
Treatment: drugs - Kaletra (lopinavir [LPVr])

Treatment: drugs: Combivir (zidovudine [AZT] / lamivudine [3TC])


Treatment: drugs: Kaletra (lopinavir [LPVr])


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine effect of 6 wks ART with LPVr and CBV, alone and in combination, in HIV negative healthy subjects with respect to changes from baseline in genes related to mitochondrial and lipid metabolism in adipocytes</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>includes: To determine the effect of 6 wks of ART with LPVr and CBV in HIV negative subjects with respect to: changes from baseline in genes related to mitochondrial and lipid and glucose metabolism in monocytes.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age &gt;18

          -  Be able to provide written consent to perform in the trial.

          -  HIV antibody negative and HIV DNA negative at time of entry to the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Any history of, or ongoing, mental or physical condition (including suspected or known
             diagnosis of ischaemic heart disease), which, in the opinion of the investigator,
             would impede the subject's ability to participate in the trial.

          -  History of type I or type II diabetes mellitus or previous treatment with antidiabetic
             medication.

          -  Prior use of testosterone, oestrogen, growth hormone or other oral glucocorticoid or
             anabolic steroid products within the previous six months.

          -  Alcohol or substance abuse which in the opinion of the investigator would affect the
             subject's ability to participate in the trial.

          -  Prior use of anti-retroviral agents (including protease inhibitors, nucleoside or
             non-nucleoside reverse transcriptase inhibitors, investigational antiretroviral agents
             or fusion inhibitors either in a previous study, as treatment or as part of
             post-exposure prophylaxis).

          -  Prior use of any retinoid-containing compound within the previous six months.

          -  Abnormal coagulation.

          -  Previous allergic reaction or known allergy to local anaesthetic.

          -  Previous use of psychotropic medications.

          -  Concomitant use of medications, including those metabolised by CYP3A4 enzyme system,
             which, in the opinion of the investigator, would affect the subject's ability to
             participate in all activities involved in the trial.

          -  Any grade-three laboratory abnormality recorded from screening bloods.

          -  Any grade-two laboratory abnormality recorded from screening bloods, which, in the
             opinion of the investigator, would impede the subject's ability to safely complete all
             study requirements.

          -  Gastrointestinal disorders, which may affect drug absorption.

          -  Any finding on screening clinical examination, which, in the opinion of the
             investigator, would impede the subject's ability to participate in the rest of the
             trial.

          -  Pregnancy

          -  Evidence of acute or chronic active hepatitis B virus infection by serology performed
             at baseline.

          -  Evidence of hepatitis C infection by serology performed at baseline.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St Vincents Hospital - Sydney</hospital>
    <postcode>2010 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>St Vincent's Hospital, Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Heart, Lung, and Blood Institute (NHLBI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Garvan Institute of Medical Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Prince of Wales Hospital, Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomised study of the effect of treatment with Combivir (zidovudine [AZT] and
      lamivudine [3TC]) and Kaletra (lopinavir [LPVr]), alone and in combination, on the
      development of abnormalities in lipid and glucose metabolism in HIV negative healthy
      subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00192621</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew D Carr, MD</name>
      <address>National Centre in HIV Epidemiology and Clinical Research.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>